Dr Norma Lynne Allgood, MD | |
5955 Zeamer Ave, 3rd Medical Group Sgh, Elmendorf Afb, AK 99506-3702 | |
(907) 580-8096 | |
Not Available |
Full Name | Dr Norma Lynne Allgood |
---|---|
Gender | Female |
Speciality | Pediatrics - Pediatric Cardiology |
Location | 5955 Zeamer Ave, Elmendorf Afb, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669445342 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2080P0202X | Pediatrics - Pediatric Cardiology | G68888 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Norma Lynne Allgood, MD 5955 Zeamer Ave, 3rd Medical Group Sgh, Elmendorf Afb, AK 99506-3702 Ph: (907) 580-8096 | Dr Norma Lynne Allgood, MD 5955 Zeamer Ave, 3rd Medical Group Sgh, Elmendorf Afb, AK 99506-3702 Ph: (907) 580-8096 |
News Archive
The Cedars-Sinai Graduate Program in Biomedical Sciences and Translational Medicine will award its first diplomas to six students during a commencement ceremony June 11.
Early and appropriate treatment by a rheumatologist may decrease costly interventions —such as orthopedic surgery — in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
Titan Spine, a developer of novel interbody fusion implants, announced today that it has received FDA clearance to commercially release its Endoskeleton® TO system, which consists of a line of interbody devices placed through a Posterior Lumbar Interbody Fusion (PLIF) approach. The company plans to commercially release the product beginning in December, 2010.
The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
› Verified 2 days ago
Rachel Claire Welsh Kennedy, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Elmendorf Afb, AK 99506 Phone: 907-580-2908 |